CoChat
Sign Up
Cited by 28Immunotherapy and Immune ResponsesT-cell and B-cell ImmunologyCancer Research and Treatments

Enhanced Immunogenicity of B Cell Lymphoma Genetically Engineered to Express Both B7-1 and Interleukin-12

Pizzoferrato, Eva, Chu, N. Randall, Hawley, Teresa S., Lieu, Francis H. L., Barber, Brian H., Hawley, Robert G., Watts, Tania H., Berinstein, Neil L.·1997·Human Gene Therapy
DOI 10.1089/hum.1997.8.18-2217
Open this paper in CoChat — free account

Abstract

The A20 murine B cell lymphoma was transfected with B7-1 and subsequently these variants and vector control variants were retrovirally infected to express murine interleukin-12 (mIL-12). In vitro data showed that the B7-1 variants enhanced secretion of IL-2 and IL-4 by allogeneic T cells in mixed lymphocyte tumor cultures. While IL-12 variants stimulated IFN-γ, variants expressing both B7-1 and IL-12 stimulated IFN-γ, IL-2, and IL-4 secretion. Tumorigenicity experiments showed that whereas B7-1 delayed tumor onset, only the mIL-12 variants with or without B7-1 were completely rejected in syngeneic hosts. In addition, tumor-free mice were protected against subsequent challenge with the parental unmodified cells and had enhanced cytotoxic T lymphocyte (CTL) lysis activity. Results from minimal disease mixing experiments demonstrated that only the A20/B7-l/mIL-12 variant was able to reject A20 unmodified cells inoculated at the same site, whereas prolonged survival was observed when the A20 parental cells were inoculated at different sites. Depletion studies and injections into nu¯/nu¯ mice demonstrated that both CD4+ and CD8+ T cells may mediate immunity. These data suggest that vaccinations with tumor cells genetically modified to express both B7-1 and IL-12 may alter cytokine profiles and generate CTL activity and, thus, the mechanisms of enhanced antitumor immunity may be multifactorial. We demonstrate that introduction of the co-stimulatory molecule B7-1 and the cytokine interleukin-12 (IL-12) can enhance the immunogenicity of a murine model of B cell lymphoma. Although IL-12 can also protect against subsequent challenge with the unmodified parental tumor cells, the combination of B7-1 and IL-12 is more potent in a minimal disease model. The mechanisms of enhancement may be multifactorial because in vivo depletion and cytotoxic T lymphocyte (CTL) studies showed that both CD4+ and CD8+ T cells are important, while in vitro data demonstrated differential cytokine production. Clearly, the effective manipulation of these molecules shows promise as a genetic intervention for the treatment of lymphoma and possibly other cancers.

Integrity signals

Registry

Crossref · 10.1089/hum.1997.8.18-2217

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A study of B-cell lymphoma cells lentivirally transduced with co-stimulatory proteins and interleukin-12 demonstrated that using these modified cells as a vaccine can result in enhanced immunogenicity to the parental lymphoma cell lines in murine models.

    “A study of B-cell lymphoma cells lentivirally transduced with co-stimulatory proteins and interleukin-12 demonstrated that using these modified cells as a vaccine can result in enhanced immunogenicity to the parental lymphoma cell lines in murine models [95].”

    From Clinical use of lentiviral vectors (2018) · cites this paper as [95]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Pizzoferrato, E., Chu, N. R., Hawley, T. S., Lieu, F. H. L., Barber, B. H., Hawley, R. G., Watts, T. H., & Berinstein, N. L.
Affiliations
  • University of Toronto (CA)
  • Sunnybrook Health Science Centre (CA)
Corresponding author
Berinstein, Neil L.
ORCID
Venue
Human Gene Therapy
Publisher
SAGE Publications
Published
1997-12-10
Volume
8
Issue
18
Pages
2217-2228
ISSN
  • 1043-0342 (ISSN-L)
  • 1557-7422
DOI
10.1089/hum.1997.8.18-2217
OpenAlex
W2005584275
Cited by
28
References
52
Citations by year
2018: 1 · 2015: 2 · 2014: 1 · 2013: 1 · 2012: 1
FWCI
1.59
Type
journal article
Language
en
Open access
closed
Licence
www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)
Locations
  • Human Gene Therapy (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University of Toronto
  • National Cancer Institute
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Cancer Research and Treatments
Keywords
CD80, IL-12, B-cell lymphoma, A20 lymphoma, tumor immunogenicity, costimulatory molecules, cytokine expression, cytotoxic T lymphocytes, antitumor immunity, tumor rejection, CD4+ T cells, CD8+ T cells, cytokine production, cancer vaccination
MeSH terms
Animals, Female, Genetic Engineering, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Nude, Neoplasms, Experimental, CD4-Positive T-Lymphocytes, Cytokines, Lymphoma, B-Cell, B7-1 Antigen, Interleukin-12, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review